914 - Fecal Microbiota Transplantation Alters Gut Microbiota in Patients with Irritable Bowel Syndrome: Results from a Randomized, Double-Blind Placebo Controlled Study

Halkjær, Sofie Ingdam; Christensen, Alice; Lo, Bobby; Browne, Patrick J.; Günther, Stig; Hansen, Lars Hestbjerg

doi:10.1016/s0016-5085(18)31016-3

Cited by 9 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FMT has been considered as a safe and efficient way to manipulate gut dysbiosis [7][8][9][10]. In this study, we demonstrated that FMT reduced serum uric acid levels in patients with gout, which is similar to the observations of the effects of FMT in mice with hyperuricemia [11].…”

Section: Discussionsupporting

confidence: 82%

“…Fecal microbiota transplantation (FMT) has been regarded as a safe and effective way to restore a healthy gut microbiota, exhibiting remarkable clinical efficacy for Clostridium difficile infection, inflammatory bowel disease and other gut dysbiosisrelated diseases [7][8][9][10]. Recently, Han et al conducted FMT in hyperuricemic mice, and found that serum uric acid levels reduced and uric acid excretion increased [11], demonstrating an ameliorating effect of FMT on hyperuricemia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of fecal microbiota transplantation on serum uric acid levels, symptoms and intestinal barrier function in patients with acute and recurrent gout: a pilot study

Xie¹,

Yang²,

Deng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gut dysbiosis has been reported to be closely associated with gout. Fecal microbiota transplantation (FMT) has been considered as an effective way to restore the balance of gut microbiota. We aimed to evaluate the effects of FMT on serum uric acid levels, gout symptoms and the intestinal barrier function in patients with acute and recurrent gout. Methods: We performed a pilot study of FMT for acute and recurrent gout. The primary outcome was the changes in serum uric acid level on day 28 post-FMT and in gout symptoms by one year. The secondary outcomes included the changes in levels of urine uric acid, diamine oxidase (DAO), D-lactic acid and endotoxin on day 28 post-FMT. The levels of DAO, D-lactic acid and endotoxin were assessed by enzyme assay. Results: Eleven patients received FMT treatment. All the patients had a reduction in serum uric acid levels after FMT treatment ( P < 0.05), accompanied with a decrease in the frequency and duration time of acute gout flares. The levels of DAO, D-lactic acid and endotoxin, reflecting the intestinal barrier function, were higher in patients with gout than in healthy donors ( P < 0.05). After FMT treatment, the levels of DAO and endotoxin decreased ( P < 0.05). Conclusions: Our findings demonstrate that FMT is effective for reducing serum uric acid levels and improving gout symptoms in patients with gout; FMT contributes to improve the impaired intestinal barrier function of the patients.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Effects of fecal microbiota transplantation on serum uric acid levels, symptoms and intestinal barrier function in patients with acute and recurrent gout: a pilot study

Xie¹,

Yang²,

Deng³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Tap et al found that the severity of IBS symptoms is negatively associated with microbial richness and enterotypes enriched with Clostridiales/Prevotella species [55] . This was further emphasized by Halkjaer et al whereby IBS patients have a lower stool microbial biodiversity, suggesting an association between IBS and gut microbiome [56] . In conjunction with this, there are some studies suggest that microbial composition varies according to IBS subtypes.…”

Section: What Is Irritable Bowel Syndrome (Ibs)?mentioning

confidence: 81%

Role of Low FODMAP Diet and Probiotics on Gut Microbiome in Irritable Bowel Syndrome (IBS)

Selvaraj¹,

Wong²,

Ser³

et al. 2020

Prog Micobes Mol Biol

View full text Add to dashboard Cite

show abstract

“…A multi-center study from the US which compared oral ingestion of encapsulated stool from healthy donors or placebo in IBS-D patients found no difference in clinical response rate between groups at week 12 (FMT 48% vs. placebo 63%, p=0.32) 68 . A final study in 52 IBS patients from Denmark reported no statistically significant benefit in IBS symptoms from encapsulated, orally administered donor stool vs. placebo at 12 weeks 69 . Thus, the efficacy of FMT for IBS remains to be clearly established.…”

Section: Microbiome-based Treatments For Irritable Bowel Syndromementioning

confidence: 95%

“…A single center trial from Belgium in 64 IBS patients with significant bloating reported a statistically significant benefit of nasojejunal administration of donor stool vs. the patient’s own stool for the primary outcome of adequate relief of IBS and bloating symptoms at 12 weeks (49% vs. 29%, p=0.004) 67 . Unfortunately, 2 additional randomized, controlled trials reported negative results 68 , 69 . A multi-center study from the US which compared oral ingestion of encapsulated stool from healthy donors or placebo in IBS-D patients found no difference in clinical response rate between groups at week 12 (FMT 48% vs. placebo 63%, p=0.32) 68 .…”

Section: Microbiome-based Treatments For Irritable Bowel Syndromementioning

confidence: 99%

The gut microbiome and irritable bowel syndrome

2018

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders encountered in clinical practice. It is a heterogeneous disorder with a multifactorial pathogenesis. Recent studies have demonstrated that an imbalance in gut bacterial communities, or “dysbiosis”, may be a contributor to the pathophysiology of IBS. There is evidence to suggest that gut dysbiosis may lead to activation of the gut immune system with downstream effects on a variety of other factors of potential relevance to the pathophysiology of IBS. This review will highlight the data addressing the emerging role of the gut microbiome in the pathogenesis of IBS and review the evidence for current and future microbiome based treatments

show abstract

914 - Fecal Microbiota Transplantation Alters Gut Microbiota in Patients with Irritable Bowel Syndrome: Results from a Randomized, Double-Blind Placebo Controlled Study

Cited by 9 publications

References 0 publications

Effects of fecal microbiota transplantation on serum uric acid levels, symptoms and intestinal barrier function in patients with acute and recurrent gout: a pilot study

Effects of fecal microbiota transplantation on serum uric acid levels, symptoms and intestinal barrier function in patients with acute and recurrent gout: a pilot study

Role of Low FODMAP Diet and Probiotics on Gut Microbiome in Irritable Bowel Syndrome (IBS)

The gut microbiome and irritable bowel syndrome

Contact Info

Product

Resources

About